Icon

VIMPAT (nda022253)- (50MG,100MG,150MG,200MG)

LACOSAMIDE UCB INC
50MG,100MG,150MG,200MG
Yes No
2022-Mar-17 Expired
None None
None No
VIMPAT is indicated for: • Treatment of partial-onset seizures in patients 1 month of age and older • Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older
15 2 12
Total Other Developers 9
Drugs with Suitability No
50MG ** ** Up - 9
100MG ** ** Up - 10
150MG ** ** Up - 10
200MG ** ** Up - 10
NDA Sales Available Total Generic Sales Available
Yes 9
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ****** **** *** * ****** ****** ******* ******* *********** ****** **. ***, ******* *******, *********** ******,, **********, ********* ******, ***** (***) ***
****** ****** ****** ****** *************** ** *** ****, *** *********** ** ********** **, **********, *** **** (**) *****-****, ****** ****** (***) ***
****** ****** ****** ****** *************** ******* ******* *********** ***/*-***, ******* ****** **** ***** *********, *****, *********, ******, ***** (***) ***
****** *** **** *** *** *** ************ ******* ******* *********** ************ ********, ****-**, ****** ***. ****& **** ** ****, ********* (*******), ********* (******), ********** ********, ********* ******, ***** (***) ***
****** *** **** *** *** *** *************** *** *********** **, **** ****, **********, *** ****** (**) *****, ****** ****** (***) ***
****** ******* ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******** ****** *** ******** *************** ******* *********** **** **. *, *****-*, ****** **** *** *********, ****, ****** ******* ******, ***** (***) ***
****** *** ***** *** ************** ********** ******* *********** ****** **. ****, *****, ***** ********* ** ***** *** ***** ****** *** ***** *** *** ******, ***** (***) ***
****** ******* ****** *** ******* ***************, ***. *********** ** ***** *****, *********, *** **** (**) *****-****, ****** ****** (***) ***
****** ****** ****** ******** ******* *********** *** *****-** & ***, *-**,**,**, ***** ********** ****, *****,, ***, *** ******, ***** (***) ***
****** ***** **** *** ***** ************ ******* *********** **** **. ***, ******* ****** ***** *****, *******, ******, *****, ***** & *** ******, ***** (***) ***
****** ********* ****** *** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ****** ****** ****** *************** ******* *********** **** **. ** *** **, **** ******** ****, ********, *****, ***** *** *** ******, ***** (***) ***
****** ******** ****** *** ****** **** *********** ******* *****, *.*. **********, ****** - *****, *****, ******** ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search





Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.